drugset / Trial / NCT04111367
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir in patients with Hepatitis C (HCV) genotype2,3,6. Efficacy was assessed by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12).
Timeline
- Start
- 2019-04-03
- Primary completion
- 2020-04-30
- Completion
- 2020-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seraprevir | Unknown | 100 mg | Oral |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |